Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results